[HPV vaccine for cervical cancer prevention].
High-risk HPV is the causative virus(requirement) for genital cancers with cervical cancer being most prevalent. Thus, theoretically, if HPV infection could be completely eradicated, most of genital cancers could be prevented. Viewed this way, HPV vaccines began to be studied about 10 years ago. Merck in the U.S. and Glaxo Smith Kline (GSK) in Europe launched full-scale development of prophylactic vaccines against HPV, and their vaccines were approved and commercially available in the worldwide. In this paper, efficacy and issues for the HPV vaccine and cancer screening in Japan are discussed.
Kawana
Kei
K
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo.
D000293:Adolescent; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008403:Mass Screening; D030361:Papillomavirus Infections; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D055502:Secondary Prevention; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*; D055815:Young Adult
D053918:Papillomavirus Vaccines